Bioventus/$BVS
1D1W1MYTD1Y5YMAX
Capital at risk
About Bioventus
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
- Ticker
- $BVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 950
- Headquarters
- Durham, United States
- Website
- www.bioventus.com
Bioventus Metrics
BasicAdvanced
$899M
16.83
$0.78
0.65
-
Price and volume
Market cap
$899M
Beta
0.65
52-week high
$15.89
52-week low
$6.26
Average daily volume
707K
Financial strength
Current ratio
1.689
Quick ratio
1.107
Long term debt to equity
0.868
Total debt to equity
0.951
Interest coverage (TTM)
3.05%
Profitability
EBITDA (TTM)
80.145
Gross margin (TTM)
68.65%
Net profit margin (TTM)
9.36%
Operating margin (TTM)
10.42%
Effective tax rate (TTM)
-59.11%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
5.49%
Return on equity (TTM)
25.68%
Valuation
Price to earnings (TTM)
16.826
Price to revenue (TTM)
1.522
Price to book
3.93
Price to tangible book (TTM)
-6.89
Price to free cash flow (TTM)
9.392
Free cash flow yield (TTM)
10.65%
Free cash flow per share (TTM)
1.401
Growth
Revenue change (TTM)
3.14%
Earnings per share change (TTM)
-6,989.26%
3-year revenue growth (CAGR)
4.45%
3-year earnings per share growth (CAGR)
-44.44%
What the Analysts think about Bioventus
Analyst ratings (Buy, Hold, Sell) for Bioventus stock.
Analyst projections of the future price of Bioventus stock.
Bulls say / Bears say
Bioventus delivered Q2 revenue of $153.2 million, up 3.8%, with Pain Treatments growing 11.5% on strong Durolane volume; management reaffirmed 2026 sales guidance of $600 million-$610 million. (SEC filing)
The company prepaid $42 million of term-loan principal during the first half of 2026, lowering interest expense and improving leverage and other credit metrics; Q2 interest expense also fell year over year. (SEC Form 10-Q)
The board initiated a strategic-alternatives review after receiving an unsolicited acquisition proposal and multiple expressions of interest, creating potential for a sale or other transaction to unlock shareholder value. (SEC filing)
Q2 revenue growth was modest at 3.8%, while Surgical Solutions declined 4.5% and Restorative Therapies fell 2.4%; this leaves growth heavily dependent on Pain Treatments and Durolane momentum. (SEC filing)
Q2 GAAP net income benefited from releasing a $24.6 million deferred-tax valuation allowance, while non-GAAP EPS rose only 5% year over year; reported earnings therefore overstate the underlying operating improvement. (SEC filing)
Bioventus faces material reimbursement, regulatory, competition, product-concentration and debt-covenant risks, including possible adverse changes affecting EXOGEN and its hyaluronic-acid products. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Bioventus Financial Performance
Revenues and expenses
Bioventus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bioventus News
AllArticlesVideos
Funds containing Bioventus
Fund name | Fund size | $BVS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.